---
title: "Life Spine Announces “Total Victory” in Patent Battle with Globus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288780682.md"
description: "Life Spine announced a 'total victory' in its patent dispute with Globus after the U.S. Court of Appeals for the Federal Circuit rejected Globus's final remaining patent claim. This ruling follows previous victories where the Patent Trial & Appeal Board cancelled claims from four patents and a jury rejected infringement on another, effectively defeating all of Globus's allegations against Life Spine's ProLift products."
datetime: "2026-06-04T22:50:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288780682.md)
  - [en](https://longbridge.com/en/news/288780682.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288780682.md)
generator: "portal-rs"
---

# Life Spine Announces “Total Victory” in Patent Battle with Globus

**Life Spine Announces “Total Victory” in Patent Battle with Globus**

Today the United States Court of Appeals, Federal Circuit, issued an opinion rejecting Globus’s last-remaining patent claim against Life Spine. 

In 2021, Globus sued Life Spine alleging that Life Spine’s ProLift® line of products infringed Globus patents. Life Spine challenged the patentability of several of the patents and, in 2024, the United States Patent Trial & Appeal Board cancelled all of the claims from four patents that Globus had asserted against Life Spine. 

In August 2025, a jury trial was held on Globus’s remaining patent claims in the United States District Court, District of Delaware. The jury rejected Globus’ infringement claims on one of the two remaining patents. Today, the Federal Circuit held that Globus’s only remaining infringement claims were based on an invalid patent. 

As a result, Life Spine has now successfully defeated all of Globus’s infringement claims. 

“This is a defining result for Life Spine,” said Rich Mueller, President & Chief Executive Officer of Life Spine. “We have always believed in the strength of our innovation and the ProLift platform. This outcome confirms what we’ve known from the beginning—that these claims lacked merit and that our technology stands on solid ground. More importantly, we remain focused on what matters most: delivering better outcomes for patients and surgeons.” 

Brianne Straka, Co-Managing Partner of Quinn Emanuel’s Chicago Office, and co-lead trial counsel, said: “It is rare to be able to defeat all patent claims asserted across eight patents. But we did it by strategically leveraging different forums. This is total victory.” 

**About Life Spine, Inc.** 

Life Spine is dedicated to improving the quality of life for spinal patients by increasing procedural efficiency and efficacy through innovative design, uncompromising quality standards, and the most technologically advanced manufacturing platforms. Life Spine, which is privately held, is based in Huntley, Illinois. For more information, please visit: http://www.lifespine.com. 

For more information:  
Mr. Joe Fricano  
Chief Financial Officer  
jfricano@lifespine.com  
847-884-6117 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260604868199/en/

### Related Stocks

- [GMED.US](https://longbridge.com/en/quote/GMED.US.md)

## Related News & Research

- [Globus Medical director Stephen T. Zarrilli disposes of 25,000 common shares worth $2.18 million](https://longbridge.com/en/news/296401521.md)
- [Is Globus Medical (GMED) Cheap After Its Earnings Beat And Higher EPS Outlook?](https://longbridge.com/en/news/295317313.md)
- [21:21 ETGlobant Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Globant (GLOB)](https://longbridge.com/en/news/296285919.md)
- [Globant Appoints Sarab Narang as CEO of Glob.AI, its new AI-native tech services model | GLOB Stock News](https://longbridge.com/en/news/296257631.md)
- [Can Globant (NYSE:GLOB) Earn Back Investor Trust At This Price?](https://longbridge.com/en/news/296016484.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**